UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000035997
Receipt number R000040956
Scientific Title Effectiveness of smartphone-based mobile application on medication adherence in patients receiving growth hormone therapy-An exploratory observational study. (GTL-App)
Date of disclosure of the study information 2019/03/01
Last modified on 2021/04/26 09:34:17

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effectiveness of smartphone-based mobile application on medication adherence in patients receiving growth hormone therapy-An exploratory observational study. (GTL-App)

Acronym

Effectiveness of smartphone-based mobile application on medication adherence in patients receiving growth hormone therapy-An exploratory observational study. (GTL-App)

Scientific Title

Effectiveness of smartphone-based mobile application on medication adherence in patients receiving growth hormone therapy-An exploratory observational study. (GTL-App)

Scientific Title:Acronym

Effectiveness of smartphone-based mobile application on medication adherence in patients receiving growth hormone therapy-An exploratory observational study. (GTL-App)

Region

Japan


Condition

Condition

Short statue caused by
-Growth hormone (GH) deficiency
-Turner syndrome
-Small for gestational age

Classification by specialty

Endocrinology and Metabolism Pediatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

-To prospectively investigate medication adherence of pediatric patients who initiate GH therapy using a smartphone-based mobile application.
-To explore factors associated with low adherence to GH therapy.

Basic objectives2

Others

Basic objectives -Others

Effectiveness of a mobile application not classified as a medical device

Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Medication adherence of patients during 24 weeks of observation period.

Key secondary outcomes

-Patients characteristics at registration.
-Time course change in medication adherence.
-Nonadherence-free survival.
-Questionnaire on GH therapy.
-Questionnaire on mobile application.
-Factors affecting adherence to GH therapy.
-Exploratory analysis of application log data.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

3 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

-Never received growth hormone therapy before.
-Aged 3 years or older.
-Planning to:
-Use GROWJECTOR-L.
-Receive seven-days-a-week
administration.
-Use type A needles.
-Written informed consent from a legally acceptable representative of the patient, along with informed assent if applicable.

Key exclusion criteria

-Contraindications for GH therapy.
eg, Diabetes, malignancy, (possible) pregnancy.
-Not supposed to be able to answer the questionnaire properly, eg, unable to read.
-Judgement of physicians.

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Tatsuhiko
Middle name
Last name Urakami

Organization

Nihon University Hospital

Division name

Department of Pediatrics

Zip code

101-8309

Address

1-6, Kanda-Surugadai, Chiyoda-ku, Tokyo 101-0062, Japan

TEL

81-3-3293-1711

Email

urakami.tatsuhiko@nihon-u.ac.jp


Public contact

Name of contact person

1st name Tatsuhiko
Middle name
Last name Urakami

Organization

Nihon University Hospital

Division name

Department of Pediatrics

Zip code

101-8309

Address

1-6, Kanda-Surugadai, Chiyoda-ku, Tokyo 101-0062, Japan

TEL

81-3-3293-1711

Homepage URL


Email

urakami.tatsuhiko@nihon-u.ac.jp


Sponsor or person

Institute

Department of Pediatrics, Nihon University Hospital

Institute

Department

Personal name



Funding Source

Organization

JCR pharmaceuticals Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethics committee of Nihon university hospital

Address

1-6, Kanda-Surugadai, Chiyoda-ku, Tokyo 101-0062, Japan

Tel

81-3-3293-1711

Email

suzuki.ikumi@nihon-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

日本大学病院をはじめとする全国約40施設を予定


Other administrative information

Date of disclosure of the study information

2019 Year 03 Month 01 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8022037/

Number of participants that the trial has enrolled

60

Results

This study enrolled 60 children with short stature from 28 Japanese medical institutions and analyzed 57 of them. The median and mean adherence rates after 24 wk of observation were 96% and 93%, respectively. Although adherence rates were significantly lower from wk 16 to wk 20 than from wk 1 to wk 4, cumulative adherence rates remained high throughout the observation period. The questionnaire analysis revealed that most patients actively used the application.

Results date posted

2021 Year 04 Month 25 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results

2021 Year 04 Month 03 Day

Baseline Characteristics

The mean age (SD) of the patients was 7.2 (3.84) yr, and the proportions of male and female patients was almost similar. A total of 54.4%, 7.0%, and 38.6% of the included patients were diagnosed with GHD, TS, and SGA, respectively. A relatively high proportion of patients were diagnosed with SGA. Among all patients, patients with SGA started GH therapy at the lowest age (P = 0.002). The baseline mean (SD) height SD score was -2.71 (0.57).

Participant flow

This study enrolled 60 patients with short stature from 28 Japanese medical institutions. Three patients discontinued shortly after GH therapy initiation due to medication change, unbearable pain, and failure to return to the hospital and were subsequently excluded from the statistical analysis.

Adverse events

N/A

Outcome measures

Good adherence rates to GH therapy were observed with the use of the treatment-supporting application. Analyses of questionnaire answers revealed that most patients actively used the application.

Plan to share IPD

N/A

IPD sharing Plan description

N/A


Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 01 Month 15 Day

Date of IRB

2019 Year 01 Month 10 Day

Anticipated trial start date

2019 Year 03 Month 01 Day

Last follow-up date

2020 Year 05 Month 31 Day

Date of closure to data entry

2020 Year 07 Month 31 Day

Date trial data considered complete

2020 Year 09 Month 30 Day

Date analysis concluded

2020 Year 12 Month 31 Day


Other

Other related information

-To prospectively investigate medication adherence of pediatric patients who initiate GH therapy using a smartphone-based mobile application.


Management information

Registered date

2019 Year 02 Month 25 Day

Last modified on

2021 Year 04 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040956


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name